Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q93100

UPID:
KPBB_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q93100; Q8N4T5

BACKGROUND:
The Phosphorylase b kinase regulatory subunit beta, with the unique identifier Q93100, is integral to the regulation of glycogen metabolism. By phosphorylating serine residues on specific substrates, it plays a key role in the control of glycogen breakdown, impacting energy availability in cells. This beta subunit serves as a regulatory element, fine-tuning the enzyme's activity in response to cellular signals.

THERAPEUTIC SIGNIFICANCE:
Linked to Glycogen storage disease 9B, a condition with mild but significant metabolic implications, the protein offers a promising target for therapeutic intervention. Exploring the mechanisms by which mutations in this protein cause disease could lead to novel approaches for managing or even curing metabolic disorders, highlighting the therapeutic potential of this protein in metabolic disease treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.